DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Osteosarcoma Recurrent, Ewing's Tumor Recurrent

In brief

The purpose of this study is to determine the feasibility of administering DL-alpha-difluoromethylornithine (DFMO) to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.

Key facts

Study ID: NCT06892678
Run by: Montefiore Medical Center
People needed: 15
Starts: 2025-04-07
Expected to finish: 2030-04-01
Last updated by the study team: 2026-05-14

Who can join

Age: any, up to 39. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients < 40 years of age at the time of enrollment
Diagnosis of relapsed osteosarcoma or relapsed Ewing sarcoma who have completed all planned therapy for their relapse, as described in the protocol, and have no evidence of disease
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
Myelosuppressive chemotherapy: At least 14 days must have elapsed since completion of myelosuppressive therapy
Monoclonal antibodies: At least 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to Grade < 2
Biologic therapy (defined as anti-cancer agents not known to be myelosuppressive): At least 7 days after the last dose of agent
Radiation therapy: At least 14 days must have elapsed after local External Beam Radiation Therapy (XRT), at least 90 days after Total Body Irradiation (TBI), craniospinal XRT or if radiation to greater than 50% of the pelvis, and at least 42 days if other substantial bone marrow radiation
Adequate bone marrow function defined as:
Peripheral absolute neutrophil count (ANC) greater or equal to 750/microliter
Platelet count greater or equal to 75,000/microliter (transfusion independent)
Adequate renal function defined by serum creatinine based on age and gender (see protocol)
Adequate liver function defined as:
Total bilirubin ≤ 1.5 x the upper limit of normal (ULN) for age AND
SGPT (ALT) ≤ 5.0 x ULN for age. For this study the ULN is 45 U/L

You may not qualify if…

Pregnant or breastfeeding females. Men and women of childbearing potential and their partners must agree to use adequate contraception while enrolled on this study. Based on the teratogenic potential of the agent, pregnant women will be excluded from this study. Because of potential risks to breastfed infants due to drug metabolites that could be excreted in breast milk, female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study. Females of childbearing potential must have a negative pregnancy test to be eligible for this study
Patients must not have an uncontrolled infection
Patients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligible

Where it is running

Montefiore Medical Center — The Bronx, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.